drugset

drugset / Trial / NCT01333540

A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

NCT01333540 ↗

Phase 2 Completed 69 enrolled Glycyx Therapeutics Theravance Biopharma · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

A dose-escalation study to assess the safety, tolerability and clinical activity of TD-1211 in patients with opioid-induced constipation.

Timeline

Start: 2011-05
Primary completion: 2012-05
Completion: 2012-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	axelopran	Small molecule	—	—

Indications